Changes in lipids and inflammation in adults with super-refractory status epilepticus on a ketogenic diet

Alex M Dickens, DPhil^{1,2}, Tory Johnson, PhD³, Santosh Lamichhane, PhD¹;
Anupama Kumar, MBBS³; Carlos A. Pardo, MD³; Erie G. Gutierrez, MD³,
Norman Haughey, PhD^{3,4}, Mackenzie C. Cervenka, MD³.

¹ Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.

² Department of Chemistry, University of Turku, Turku, Finland.

³ Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 21287.

³ Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 21287.

Word Count:

3,578 (4500 Words)

250 (250 Word Abstract)

247 (250 Word Introduction)

50 (50 references)

6 Figures/2 Tables

Study Funding: This study was funded by the Johns Hopkins Center for Status Epilepticus and Neuroinflammation.

5 Search Terms: lipid, inflammation, status epilepticus, epilepsy, ketogenic

Disclosures:

1. Alex Dickens, PhD

Disclosure: Dr Dickens has worked part time for Orion Pharma (Finland). This study has nothing to do with his work at this company.

2. Tory Johnson, MD

Disclosure: Dr. Johnson has no relevant disclosures.

3. Santosh Lamichhane, PhD

Disclosure: Dr. Lamichhane has no relevant disclosures.

4. Anupama Kumar, MBBS

Disclosure: Dr. Kumar has no relevant disclosures.

5. Carlos A. Pardo, MD

Disclosure: Dr. Pardo has no relevant disclosures.

6. Erie G. Gutierrez, MD

Disclosure: Dr. Gutierrez has no relevant disclosures.

7. Norman Haughey, PhD

Disclosure: Dr. Haughey has no relevant disclosures.

8. Mackenzie C. Cervenka, MD

Disclosure: Dr. Cervenka receives grants from Nutricia, Vitaflo, BrightFocus Foundation, and Army Research Laboratory. Honoraria from American Epilepsy Society, The Neurology Center, Epigenix, LivaNova, and Nutricia. Royalties from Demos Health/Springer Publishing Company. Consulting for Nutricia, Sage Therapeutics.

Abstract

Objective: To test the hypothesis that increased ketone body production with a ketogenic diet (KD) will correlate with reductions in pro-inflammatory cytokines, lipid subspecies, and improved clinical outcomes in adults treated with an adjunctive ketogenic diet for super-refractory status epilepticus (SRSE).

Methods: Adults (18 years or older) were treated with a 4:1 (fat:carbohydrate and protein) ratio enteral KD as adjunctive therapy to pharmacologic seizure suppression for SRSE. Blood and urine samples and clinical measurements were collected at baseline (n=10), after 1 week (n=8), and after 2 weeks of KD (n=5). Urine acetoacetate, serum β -hydroxybutyrate, lipidomics, pro-inflammatory cytokines (IL-1 β , IL-6), chemokines (CCL3, CCL4, CXCL13), and clinical measurements were obtained at these 3 time points. Univariate and multivariate data analyses were performed to determine the correlation between ketone body production and circulating lipids, inflammatory biomarkers, and clinical outcome.

Results: Changes in lipids included an increase in ceramides, mono-hexosyl ceramide, sphingomyelin, phosphocholine, and phosphoserines, and there was a significant reduction in pro-inflammatory mediators IL-6 and CXCL13 seen at 1 and 2 weeks of KD. Higher blood β -hydroxybutyrate levels at baseline correlated with better clinical outcome however, ketone body production did not correlate with other variables during treatment. Higher chemokine CCL3 levels following treatment correlated with greater length of intensive care unit stay, higher modified Rankin Scale score (worse neurologic disability) at discharge and 6-month follow up.

Conclusions: Adults receiving an adjunctive enteral ketogenic diet for super-refractory status epilepticus have alterations in select pro-inflammatory cytokines and lipid species that may predict response to treatment.

Introduction

Status epilepticus (SE) is the second most frequent neurologic emergency worldwide¹⁻³. Super-refractory status epilepticus (SRSE)⁴, SE that persists despite 24 hours of aggressive intervention, carries an in-hospital mortality rate above 40%^{5, 6}. The ketogenic diet (KD) is a high fat, carbohydrate-restricted diet that shows promise for treating SRSE and may do so through fatty acid metabolism,^{7, 8-12, 13, 14}. A study using a 4:1 ratio KD in 15 adults with SRSE found that 73% had resolution of SRSE, and more recent studies have replicated these findings^{12, 15, 16}.

The exact mechanisms by which KD stops status epilepticus remain under investigation. During prolonged status epilepticus, systemic inflammation leads to loss of blood-brain-barrier integrity, leakage of neurotoxic serum proteins into the brain, and loss of inhibitory interneurons, all promoting further neuronal hyperexcitability¹⁷⁻²¹. Specific pro-inflammatory cytokines and chemokines including IL-1 β , IL-6, CCL2, and CCL3 significantly increase with disease progression²²⁻³². KD reduces inflammation thereby potentially halting this cyclical progression of neuronal injury and death³³⁻³⁸.

Another potential mechanism of action of KD may be lipid modulation that occurs when fatty acids are utilized during carbohydrate restriction. Certain lipid subspecies have been shown to be anti-inflammatory which may also explain the impact of KD on the inflammatory cascade³⁸. This study examines the relationship between systemic inflammation, lipid modulation, and clinical outcomes in adults on a KD for management of SRSE. We hypothesized that increased ketone body production would correlate with reduction in pro-inflammatory cytokines, pro-inflammatory lipid subspecies, and improved clinical outcomes.

Methods

Population and demographics

The patients included in this study have previously been described³⁹. Briefly, 15 patients with SRSE were recruited into a phase I/II clinical trial, and of these, 10 were included in this study. The ethical standards committee on human experimentation Johns Hopkins Medicine Institutional Review Board (JHM IRB) approved this experiment using human participants including biospecimen collection and participation in the clinical trial (JHM IRB study numbers NA_00003551 and [NA_00073063](#), respectively). Written informed consent was obtained from all participants (or guardians of participants) in the study (consent for research). The original clinical trial from which participant biospecimens were collected was reported on ClinicalTrials.gov (NCT01796574). The patients were treated with a 4:1 (fat: carbohydrate and protein in grams) ratio KD upon diagnosis or hospital transfer. Clinical characteristics included participant age, gender, race, history of epilepsy prior to admission, and etiology of SRSE. “Ketosis” was defined as urine acetoacetate ≥ 40 mg/dL and/or serum β -hydroxybutyrate ≥ 2 mmol/L in order to calculate time to ketosis as a clinical outcome variable. Aliquots of plasma were collected from the patients repeatedly over time at 1-week intervals when possible. The plasma was stored at -80 °C prior to analysis. Due to the low number of samples longitudinally, we categorized the patients into 4 groups defined as follows:

- Baseline: Blood samples taken prior to the start of the ketogenic diet (n=10)
- Week 1: Blood samples taken after 1 week of ketogenic diet (n=8)
- Week 2: Blood samples taken after 2 weeks of ketogenic diet (n=5)

Plasma lipid extraction

The lipids were extracted from the plasma using a modified Bligh Dyer approach. Throughout the procedure all steps were performed with glass to avoid extracting lipid like structures from lab plastic ware. All solvents used were of ultra-pure HPLC grade. 30 μ L of plasma was mixed gently with 970 μ L ddH₂O and 2.9 μ L mix of MeOH:DCM (2:0.9 v/v) to form a monophasic mixture. The organic fraction had a mix of the following lipids as internal standards: N-lauroyl-D-erythro-sphingosine (Cer d18:1/12:0, 6 ng/mL), 1,3(d5)-dihexadecanoyl-glycerol (d5-DAG d16:0/16:0, 12.5 ng/mL), D-galactosyl- β -1,1' N-lauroyl-D-erythro-sphingosine (GlcCer d18:1/12:0, 3.3 ng/mL), D-lactosyl- β -1,1' N-lauroyl-D-erythro-sphingosine (LacCer 18:1/12:0, 10.6 ng/mL), 1,3(d5)-dihexadecanoyl-2-octadecanoyl-glycerol (D-5 TAG 16:0/18:0/16:0, 0.5 ng/mL), cholesteryl-d7 palmitate (cholesteryl-d7 ester 16:0, 30 ng/mL), 1,2-dilauroyl-sn-glycero-3-phosphate (sodium salt) (PA d12:0/12:0, 1025 ng/mL), 1,2-dilauroyl-sn-glycero-3-phosphocholine (PC 12:0/12:0, 0.2 ng/mL), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (PE d12:0/12:0, 1.6 ng/mL), 1,2-dilauroyl-sn-glycero-3-phospho-[1'-rac-glycerol] (PG d12:0/12:0, 200 ng/mL), 1,2-dilauroyl-sn-glycero-3-phospho-L-serine (PS d12:0/12:0), N-lauroyl-D-erythro-sphingosylphosphorylcholine (SM d18:1/12:0, 0.3 ng/mL), all internal standards were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). 1 mL of ddH₂O and 0.9 mL of DCM was added to the mixture and the sample was briefly vortexed resulting in a biphasic mixture. This mixture was allowed to stand for 30 mins on ice prior to centrifugation (10 min, 3000g, 4 °C). The organic phase was then removed and stored at -20 °C until the mass spectrometry analysis.

Mass spectrometry analysis

Prior to the mass spectrometry analysis 1 mL of the organic extract was evaporated to dryness under a stream of nitrogen and re-suspended in the running solvent (250

μL, MeOH:DCM, 1:1, containing 5 mM NH₄CH₃). The running solvent also contained 5mg/mL of ceramide C17:0 as a further internal standard to monitor instrument performance over time independently of the extraction process. The concentration of the lipids were then measured using an MS/MS^{ALL} experiment in positive mode on a TripleTOFTM 5600 (Sciex, USA) mass spectrometer. This is a data independent acquisition mode where the first quad steps through all masses from 200 to 1200 Da in 1 Da steps. The selected precursor ion was then fragmented and quantified by the TOF with a scan range of 100-1500 Da. The accumulation time was set to 450 ms and the data was acquired using Analyst 1.7 TF (Sciex, USA) software. The mass calibration was performed after the run based on the internal standards within the sample. The sample (50 μL) was continually infused into the spectrometer at a constant flow rate (5 μL/min) using a LC-20AD pump and SIL-20AC XR HPLC system (Shimadzu, USA). The source parameters of the mass spectrometer was set up as follows: ion source gases 15 psi (GSI) and 20 psi (GS2), curtain gas 30 psi, temperature 150 °C, positive ion spray voltage +5500V, declustering potential at 80 V and collision energy at 10V. All samples were run in duplicate.

Identification of lipids

In order to build a targeted method to extract out the identified lipids from each sample, a pooled sample was run eight times using the same mass spectrometry method. The lipids were then identified based on their fragmentation patterns using Lipid View (Sciex, USA). Each lipid species identified had to appear in 7 out of the 8 replicates and have a coefficient of variation below 20% in order for it to be included in the targeted lipid list. The resultant lipid list was then used to create a targeted method for extracting these specific lipids in Lipid View (Sciex, USA). The method was then applied to all the samples using MultiQuant v3.0 (Sciex, USA). The lipids

intensities were corrected to their relevant class based internal standard. If the duplicate samples varied by more than 30% in intensity then the samples were re-run. For statistical analysis zero intensities were imputed by dividing the lowest intensity lipid by a factor of 1000.

Cytokine and chemokine quantification

Serum IL-1 β , IL-6, TNF α , CCL3, CCL4, and CXCL13 concentrations were measured serially in six participants by microbead multiplexed assays (Luminex®) per the manufacturer's instructions. Only those participants that were not treated with concomitant immunosuppression were included in cytokine and chemokine analyses. Cytokine levels were measured prior to initiation of the ketogenic diet and at one and or two weeks after diet initiation when possible.

Statistical analysis

The univariate analysis of lipid changes over time was assessed using a Wilcoxon rank test with multiple test correction. PLS-DA multivariate statistical analysis was performed using the PLS toolbox v 8.5 (Eigenvector labs, USA) for MATLAB 2018a (MathWorks, USA). The PLS-DA models were cross validated with a leave-one-out approach due to the low number of samples. Block variance scaling were used to scale the multiblock data. Multiblock-ANOVA-simultaneous component analysis (ASCA) a multivariate extension of ANOVA analysis was performed to allow interpretation of the variation induced categorical factors including Case (Baseline vs Week1), Sex, Race and history of epilepsy prior to admission. This multivariate analysis was also done using the PLS Toolbox 8.2.1 (Eigenvector Research Inc., Manson, WA, USA) in MATLAB 2017b (MathWorks, Inc., Natick, MA, USA).

All univariate analysis and resultant bar graphs were performed in Prism v 7.04 (GraphPad, USA). For the 4 group comparisons one way-ANOVA tests were used and multiple comparisons were corrected using the Benjamini and Hochberg FDR. Significant changes were defined as q values less than 0.05. Spearman correlation coefficients were calculated using the statistical toolbox in MATLAB 2017b and p-

values < 0.05 (two-tailed) were considered significant for the correlations. The individual Spearman correlation coefficients (R) were illustrated circular correlation plot using the 'corrplot' package for the R statistical programming language.

For any missing values the half minima of that variable was used impute the value.

Cytokine and chemokine results are presented as index to control with the pre-ketogenic baseline measure set to 100%. Per previously described analyses strategies, if a measurement was below the limit of detection for a patient it was assigned the value of half the limit of detection and if more than one measurement was below the limit of detection for the same patient that patient was excluded from analysis⁴⁰. Measurements were assessed for statistical outliers and outliers (patient 8 CCL3 measurement, patient 1 CCL4 measurement, patient 10 TNF- α measurement, and patient 3 CXCL13 measurement) were not included in analyses but are presented in the figures. Decreases in cytokine or chemokine concentrations from baseline after initiation of the ketogenic diet were compared using a one-tailed paired t-test with a $P < 0.05$ considered statistically significant. Statistical analyses were performed with GraphPad Software version 8.3.1.

Model-Based Clustering

Clustering of the lipidomic data was applied by using the *mclust* R package (version 5.4.5). *mclust* is a model-based clustering method where the model performances are evaluated by the Bayesian information criterion. Generally, the model with the highest Bayesian information criterion is chosen.

Results

Circulating lipids and cytokines

There were a total of 487 lipids detected and identified in serum from study participants. In addition, a panel of 6 cytokines and chemokines were also measured from the same samples. See Figure 1 for the overall experimental design.

Lipid changes with ketogenic diet

Using a univariate approach, we identified a total of nine lipids that changed in abundance from baseline to week 1, and 29 lipids that changed in abundance by week 2, with $q = 0.1$ (see Table 1). Unknown triacylglycerol (TAG) species (54:11) and TAG (54:5) consistently increased from baseline to week 1, and from week 1 to week 2.

Building an ASCA model using the individual lipidomic data from available samples we observed a clear drift in the multivariate models (Figure 2A), suggesting that there was a clear change in the serum lipid content after participants were placed onto a ketogenic diet that persisted over time. To further explore this change in serum lipid content over time we utilized an ANOVA-simultaneous component analysis (ASCA) multivariate model. This model can determine the effects of different independent variables such as time within the data in a manner similar to a standard two-way ANOVA. The ASCA modelling (Figure 2B) showed a distinct effect of time on ketogenic diet (effect = 12.5%) and gender (6.3%). Examination of the loadings of the first principal component for the factor of time on ketogenic diet demonstrated that several classes of lipids increased over time including ceramides,

mono-hexosyl ceramides, sphingomyelins, phosphocholines, and phosphoserines (Figure 2C).

From the univariate model there was a clear change in the triglyceride species. Therefore, we plotted how these changed over time. Interestingly the short chain unsaturated lipids decreased in concentration whilst on the diet whereas the longer and more saturated compounds increased (Figure 3). These shorter chain saturated TAGs result from *de novo* lipogenesis suggesting that the ketogenic diet is actively suppressing this metabolic pathway. The larger unsaturated species result from the diet and this is to be expected given the diet these patients are on.

Serum cytokine changes over time

Two cytokines, IL-1 β or TNF α were excluded from further analysis as only two participants had measurable levels above the limits of detection for the assay. IL-6 (n=5), CCL3 (n=5), CCL4 (n=6), and CXCL13 (n=6) concentrations were reliably measured in paired samples in participants and concentrations of each cytokine were normalized to individual participant at baseline and compared after one to two weeks on the ketogenic diet (Figure 4). Despite the small number of samples with detectable levels of cytokines pre- and post- treatment, there was a significant reduction in IL-6 (Figure 4A) at 1-2 weeks post-ketogenic diet compared to baseline (mean $\pm$ SD, pre-diet 100 $\pm$ 0 versus post-diet 43.8 $\pm$ 24.7, p=0.0013, one-way paired t-test). No differences in CCL3 (Figure 4B) (mean $\pm$ SD, pre-diet 100 $\pm$ 0 versus post-diet 166.1 $\pm$ 302.6, P=0.3458, one-way paired t-test) or CCL4 (Figure 4C) (mean $\pm$ SD, pre-diet 100 $\pm$ 0 versus post-diet 85.87 $\pm$ 22.02, P=0.1124, one-way paired t-test) were detected, although previously found to decrease in one preclinical studies of ketogenic diet⁴¹. An outlier (patient three) was detected in

measurements for CXCL13 (Figure 4D) and therefore this patient was excluded from analyses. There was a significant reduction in CXCL13 after the ketogenic diet as compared to pre-diet (mean $\pm$ SD, pre-diet 100 ± 0 versus post-diet 58.36 ± 33.56 , $P=0.025$, one-way paired t-test).

Associations between serum lipids and cytokines

Due to the large number of lipids detected in the serum and the high degree of cross correlation associated with lipidomic data we decided to reduce the dimensionality of the data using Bayesian clustering which has previously been used for lipid datasets. This technique clusters the lipids which behave in a similar fashion together. As expected the lipids largely clustered based on their class. When plotting the average lipid concentration for each cluster only a few clusters showed a change over time. These clusters were: cluster 3 ($p = 0.0445$) and cluster 12 ($p = 0.0089$). To see the lipids which are contained in each cluster see Table 2. Lipid cluster 3 contained a broad species of lipids but primarily it contained lipids which were related to inflammation such as Cer, SM and oxidized lipids. Lipid cluster 12 contained large unsaturated TAGs which is a result of the diet. When looking at the association of the lipids and cytokines and clinical characteristics there was a high degree of correlation between the lipid clusters as expected (Figure 5 A&B). At baseline, there were positive correlations between lipid cluster 4 and 6 with IL-6 and CCL3. Lipid cluster 4 contained ceramides and sphingomyelins as well as some diacylglycerols (DAGs), TAGs and unknown TAG species. Lipid cluster 6 contains predominantly unknown TAG species and TAGs. Additionally, there was a positive correlation with lipid cluster 5 and CCL4. There were further positive correlations between IL-1 β and lipid cluster 11 and cluster 1 with TNF α . There was also a negative association between TNF α and lipid clusters 4, 5 and 8. Furthermore, there was a negative

association between lipid cluster 1 and IL-6. At baseline the only lipid cluster which positively correlated to the clinical features was lipid cluster 4. This lipid cluster was associated with a history of epilepsy prior to admission for SRSE. For more information about the other lipid classes see Table 2. After 1 week of the ketogenic diet there was an even stronger correlation between the lipid clusters suggesting that the diet may alter lipid metabolism in patients with SRSE. Interestingly, the patterns observed with the cytokines changed following diet initiation. Lipid cluster 2 is became positively associated with IL-1 β and TNF α . Lipid cluster 2 contains lyso-lipids which have been shown to be altered in a pro-inflammatory state⁴². The only other significant associations between lipids and cytokines were all positive and linked lipid cluster 4 with IL6 and CCL3. CCL3 was also associated with lipid cluster 7, 8, 9, and 10 which contain the TAG species.

Lipids and inflammatory biomarkers as predictors of clinical outcome

Due to the low number of participants, making predictions on the whole circulating lipidome is very difficult. However, it was possible to build a PLS-DA model using the week 1 blood samples which could differentiate between the participants who recovered with only a mild disability (mRS < 3) compared to those who were moderately or more severely disabled or dead (mRS $\geq$ 3) (Figure 6A). The cross-validated model had an ROC = 0.56 which is understandable given the very small sample size (n=4 per group). However, from the PLS-DA model it was possible to identify which lipids cause the separation observed in the model by examining the variable importance scores which provides a metric on how each lipid contributes to the PLS-DA model.

At baseline (Figure 5), there were very few significant correlations between pro-inflammatory and lipid biomarkers and clinical outcomes. There was a significant negative correlation between GCS score at discharge and CXCL13 levels prior to diet intervention. In other words, those participants with higher CXCL13 levels prior to diet intervention had poorer neurologic outcomes. There was a strong negative correlation between blood β -hydroxybutyrate levels at baseline and mRS at discharge and 6-month follow up. In other words, participants with lower blood ketone levels prior to intervention had more severe disability or higher likelihood of death at discharge and at 6 months.

At 1 week, there were several significant correlations between lipid clusters, CCL3 concentrations, and clinical outcomes. While it was previously noted that CCL3 levels positively correlated with lipid clusters 4, 7, 8, 9, and 10 concentrations, higher CCL3 levels also correlated with greater length of ICU stay and higher mRS score (worse neurologic disability) at discharge and 6-month follow up. There was also a significant positive correlation between mRS at discharge and lipid cluster 9. Finally, there was a negative correlation between CCL3 concentrations at 1 week as well as lipid clusters 7, 8, and 9 and GCS scores at discharge.

Discussion

Super-refractory status epilepticus is a life-threatening disease with no proven treatments. While the ketogenic diet (KD) has been used for nearly one century to manage seizure disorders, it has only been incorporated into the management of refractory and super-refractory status epilepticus in the last decade. This study was designed to determine whether treatment with a ketogenic diet and resultant production of ketone bodies played a role in lipid modulation and reduction in

systemic inflammation as potential mechanisms of action for stopping seizures in adults with super-refractory status epilepticus.

Prior to initiation of the ketogenic diet in adults with SRSE, there were several positive correlations between clusters of lipid species and pro-inflammatory cytokine and chemokine levels. There was a specific association with prior history of epilepsy and a lipid cluster which contained ceramides and sphingomyelins as well as some diacylglycerols, triacylglycerols, and monoalkyldiacylglycerol (unknown TAG species), suggesting that the prior epilepsy could have long term effects on these lipids or that these changes could be the underlying cause⁴³. The associations of these lipid clusters to pro-inflammatory cytokines⁴⁴ suggests that they may be markers of the underlying inflammation.

Ceramides are a subclass of sphingolipids that are known to regulate the surface expression of NMDA receptors⁴⁴, and to mediate programmed cell death. Ceramides have been shown to increase in hippocampal tissue of adult rats after kainic acid-induced status epilepticus^{43, 45}, suggesting a potential role in neuronal injury during status epilepticus. In the study, the levels of ceramides and hexyl ceramides increased over time.

The only biomarker that significantly predicted clinical outcome prior to KD initiation was β -hydroxybutyrate level. Specifically, higher β -hydroxybutyrate levels prior to intervention predicted lower degree of disability at discharge and 6-month follow up. In a lipopolysaccharide-induced fever rodent model, researchers observed a less fever and lower pro-inflammatory cytokines IL-1 β and TNF α in animals pre-treated with KD compared to controls although ketone body measures were not included³⁸. The authors concluded that KD may have a neuroprotective effect. In RSE and

SRSE, it is well-established that early aggressive intervention reduces morbidity and mortality and therefore, participants who were producing ketone bodies prior to KD (either with fasting or other lipid sources pre-diet) may have derived benefit even prior to diet initiation.

There was a significant reduction in systemic pro-inflammatory cytokine IL-6 and pro-inflammatory chemokine CXCL13 on KD. Recent studies have shown that the ketone body β -hydroxybutyrate directly inhibits NLRP3 inflammasome-mediated production of IL-1 β ⁴⁶⁻⁴⁸, reducing systemic inflammation in rodents and human monocytes, which may provide an explanation for the reduction in systemic pro-inflammatory cytokines and chemokines observed in this study. However, urine acetoacetate and blood β -hydroxybutyrate as well as time to ketosis did not show any direct correlation with clinical outcomes or inflammatory biomarker concentrations in this study. Prior studies examining the relationship between ketone body production and seizure cessation in humans have had mixed results, likely due to a small number of participants⁴⁹.

At the conclusion of the study, higher CXCL13 levels correlated with poorer neurologic outcomes. Recent studies have demonstrated increase in CXCL13 in rodent models of status epilepticus and postulated that this may play a role in pathogenesis⁵⁰. Lower levels of CCL3 and lipid clusters 7-9 predicted better clinical outcome at 1 week of intervention with KD.

This study had several important limitations. The number of participants was small and therefore few significant correlations could be identified. In addition, serial sample collection was not feasible for all participants and IL-1 β and TNF α measures were below the detectable range in most participants. Expected changes in lipids

and inflammatory cytokine and chemokine concentrations with progression of SRSE are unknown and therefore which changes may have been a result of KD or ketone body production cannot be determined.

In conclusion, this study provides preliminary evidence that lipid modulation and reduction in pro-inflammatory biomarkers occur during administration of a ketogenic diet in adults with super-refractory status epilepticus. Furthermore, lower levels of pro-inflammatory chemokines and certain lipid species predict better neurologic outcome following KD. Further studies are needed to understand the potential neuroprotective effects of lipid modulation and reduction in inflammation using KD in the setting of refractory status epilepticus and to establish the relationship between modulation of specific lipid species, inflammation, ketone body production, and seizure cessation.

Acknowledgements

We would like to thank the patients and families who participated in this study. This study was funded by the generous philanthropic support through the Johns Hopkins Center for Status Epilepticus and Neuroinflammation from Chris Garrod and Dawn Griffiths. We would also like to thank Jacqueline Lovett for sample collection and processing and Bareng Nonyane and Ximin Li for biostatistical support.

References

1. Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. *Epilepsia* 2001;42:714-718.
2. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. *Lancet Neurol* 2011;10:922-930.
3. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. *Neurology* 1996;46:1029-1035.
4. Hocker S, Tatum WO, LaRoche S, Freeman WD. Refractory and super-refractory status epilepticus--an update. *Curr Neurol Neurosci Rep* 2014;14:452.
5. Jayalakshmi S, Ruikar D, Vooturi S, et al. Determinants and predictors of outcome in super refractory status epilepticus--a developing country perspective. *Epilepsy Res* 2014;108:1609-1617.
6. Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F. Costs, length of stay, and mortality of super-refractory status epilepticus: A population-based study from Germany. *Epilepsia* 2017;58:1533-1541.
7. Cervenka MC, Kossoff EH. Dietary treatment of intractable epilepsy. *Continuum (Minneapolis)* 2013;19:756-766.
8. Wusthoff CJ, Kranick SM, Morley JF, Christina Bergqvist AG. The ketogenic diet in treatment of two adults with prolonged nonconvulsive status epilepticus. *Epilepsia* 2009;51:1083-1085.
9. Nam SH, Lee BL, Lee CG, et al. The role of ketogenic diet in the treatment of refractory status epilepticus. *Epilepsia* 2011;52:e181-184.
10. Cervenka MC, Hartman AL, Venkatesan A, Geocadin RG, Kossoff EH. The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit. *Neurocrit Care* 2011;15:519-524.
11. Thakur KT, Probasco JC, Hocker SE, et al. Ketogenic diet for adults in super-refractory status epilepticus. *Neurology* 2014;82:665-670.
12. Peng P, Peng J, Yin F, et al. Ketogenic Diet as a Treatment for Super-Refractory Status Epilepticus in Febrile Infection-Related Epilepsy Syndrome. *Frontiers in neurology* 2019;10:423.
13. Lin JJ, Lin KL, Chan OW, Hsia SH, Wang HS. Intravenous ketogenic diet therapy for treatment of the acute stage of super-refractory status epilepticus in a pediatric patient. *Pediatr Neurol* 2015;52:442-445.
14. Strzelczyk A, Reif PS, Bauer S, et al. Intravenous initiation and maintenance of ketogenic diet: proof of concept in super-refractory status epilepticus. *Seizure* 2013;22:581-583.
15. Park EG, Lee J, Lee J. The ketogenic diet for super-refractory status epilepticus patients in intensive care units. *Brain Dev* 2019.
16. Francis BA, Fillenworth J, Gorelick P, Karanec K, Tanner A. The Feasibility, Safety and Effectiveness of a Ketogenic Diet for Refractory Status Epilepticus in Adults in the Intensive Care Unit. *Neurocrit Care* 2018.
17. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. *Epilepsia* 2005;46:1724-1743.
18. Vezzani A, Aronica E, Mazarati A, Pittman QJ. Epilepsy and brain inflammation. *Experimental neurology* 2013;244:11-21.

19. Ravizza T, Balosso S, Vezzani A. Inflammation and prevention of epileptogenesis. *Neurosci Lett* 2011;497:223-230.
20. Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: excitability and inflammation. *Trends in neurosciences* 2013;36:174-184.
21. Librizzi L, Noe F, Vezzani A, de Curtis M, Ravizza T. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage. *Annals of neurology* 2012;72:82-90.
22. Pernot F, Heinrich C, Barbier L, et al. Inflammatory changes during epileptogenesis and spontaneous seizures in a mouse model of mesiotemporal lobe epilepsy. *Epilepsia* 2011;52:2315-2325.
23. Kan AA, van der Hel WS, Kolk SM, et al. Prolonged increase in rat hippocampal chemokine signalling after status epilepticus. *Journal of neuroimmunology* 2012;245:15-22.
24. Fabene PF, Bramanti P, Constantin G. The emerging role for chemokines in epilepsy. *Journal of neuroimmunology* 2010;224:22-27.
25. Aronica E, Crino PB. Inflammation in epilepsy: clinical observations. *Epilepsia* 2011;52 Suppl 3:26-32.
26. Ravizza T, Vezzani A. Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1 receptor type I in the rat limbic system. *Neuroscience* 2006;137:301-308.
27. Eriksson C, Tehranian R, Iverfeldt K, Winblad B, Schultzberg M. Increased expression of mRNA encoding interleukin-1beta and caspase-1, and the secreted isoform of interleukin-1 receptor antagonist in the rat brain following systemic kainic acid administration. *Journal of neuroscience research* 2000;60:266-279.
28. De Simoni MG, Perego C, Ravizza T, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. *The European journal of neuroscience* 2000;12:2623-2633.
29. Lv R, Xu X, Luo Z, Shen N, Wang F, Zhao Y. Pyrrolidine dithiocarbamate (PDT) inhibits the overexpression of MCP-1 and attenuates microglial activation in the hippocampus of a pilocarpine-induced status epilepticus rat model. *Experimental and therapeutic medicine* 2014;7:39-45.
30. Hung YW, Lai MT, Tseng YJ, Chou CC, Lin YY. Monocyte chemoattractant protein-1 affects migration of hippocampal neural progenitors following status epilepticus in rats. *Journal of neuroinflammation* 2013;10:11.
31. Foresti ML, Arisi GM, Katki K, Montanez A, Sanchez RM, Shapiro LA. Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus. *Journal of neuroinflammation* 2009;6:40.
32. Zhu XB, Wang YB, Chen O, et al. Characterization of the expression of macrophage inflammatory protein-1alpha (MIP-1alpha) and C-C chemokine receptor 5 (CCR5) after kainic acid-induced status epilepticus (SE) in juvenile rats. *Neuropathology and applied neurobiology* 2012;38:602-616.
33. Yang X, Cheng B. Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP-induced neurotoxicity. *J Mol Neurosci* 2010;42:145-153.
34. Fraser DA, Thoen J, Bondhus S, et al. Reduction in serum leptin and IGF-1 but preserved T-lymphocyte numbers and activation after a ketogenic diet in rheumatoid arthritis patients. *Clin Exp Rheumatol* 2000;18:209-214.
35. Fraser DA, Thoen J, Djoseand O, Forre O, Kjeldsen-Kragh J. Serum levels of interleukin-6 and dehydroepiandrosterone sulphate in response to either fasting or a ketogenic diet in rheumatoid arthritis patients. *Clin Exp Rheumatol* 2000;18:357-362.

36. Schreck KC, Lwin M, Strowd RE, Henry-Barron BJ, Blakeley JO, Cervenka MC. Effect of ketogenic diets on leukocyte counts in patients with epilepsy. *Nutritional neuroscience* 2017;1-6.
37. Buyken AE, Goletzke J, Joslowski G, et al. Association between carbohydrate quality and inflammatory markers: systematic review of observational and interventional studies. *Am J Clin Nutr* 2014.
38. Dupuis N, Curatolo N, Benoist JF, Auvin S. Ketogenic diet exhibits anti-inflammatory properties. *Epilepsia* 2015;56:e95-98.
39. Cervenka MC, Hocker S, Koenig M, et al. Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus. *Neurology* 2017;10.1212/WNL.0000000000003690.
40. Beal SL. Ways to fit a PK model with some data below the quantification limit. *J Pharmacokinet Pharmacodyn* 2001;28:481-504.
41. Kim do Y, Hao J, Liu R, Turner G, Shi FD, Rho JM. Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. *PLoS One* 2012;7:e35476.
42. Frasch SC, Bratton DL. Emerging roles for lysophosphatidylserine in resolution of inflammation. *Prog Lipid Res* 2012;51:199-207.
43. Mikati MA, Abi-Habib RJ, El Sabban ME, et al. Hippocampal programmed cell death after status epilepticus: evidence for NMDA-receptor and ceramide-mediated mechanisms. *Epilepsia* 2003;44:282-291.
44. Wheeler D, Knapp E, Bandaru VV, et al. Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. *Journal of neurochemistry* 2009;109:1237-1249.
45. Mikati MA, Abi-Habib RJ, El Sabban ME, et al. Hippocampal programmed cell death after status epilepticus: evidence for NMDA-receptor and ceramide-mediated mechanisms. *Epilepsia* 2003;44:282-291.
46. Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. *Nature medicine* 2015;21:263-269.
47. Deora V, Albornoz EA, Zhu K, Woodruff TM, Gordon R. The Ketone Body beta-Hydroxybutyrate Does Not Inhibit Synuclein Mediated Inflammasome Activation in Microglia. *J Neuroimmune Pharmacol* 2017;12:568-574.
48. Yamanashi T, Iwata M, Kamiya N, et al. Beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses. *Scientific reports* 2017;7:7677.
49. Buchhalter JR, D'Alfonso S, Connolly M, et al. The relationship between d-beta-hydroxybutyrate blood concentrations and seizure control in children treated with the ketogenic diet for medically intractable epilepsy. *Epilepsia Open* 2017;2:317-321.
50. Li R, Ma L, Huang H, et al. Altered Expression of CXCL13 and CXCR5 in Intractable Temporal Lobe Epilepsy Patients and Pilocarpine-Induced Epileptic Rats. *Neurochemical research* 2017;42:526-540.

Table 1

Lipid	Week 1 Q	Week 2 Q
Unknown TAG species (54:11)	0.090	0.094
TAG (58:7)	0.090	0.236
TAG (54:4)	0.090	0.134
TAG (54:5)	0.090	0.070
TAG (54:4)	0.090	0.134
TAG (54:3)	0.090	0.276
PS_O (34:6)	0.090	0.386
HexCer(30:0;2)	0.090	0.457
TAG (58:5)	0.090	0.276
TAG (54:4)	0.110	0.078
TAG (54:5)	0.110	0.081
TAG (56:4)	0.110	0.081
TAG (56:5)	0.110	0.092
TAG (56:7)	0.116	0.022
TAG (56:5)	0.116	0.078
HexCer (26:1;3)	0.116	0.081
Unknown TAG species (54:9)	0.116	0.092
Unknown TAG species (54:10)	0.126	0.078
TAG (56:6)	0.186	0.022
TAG (56:4)	0.186	0.081
TAG (56:7)	0.199	0.015
TAG (56:6)	0.207	0.081
Unknown TAG species (54:11)	0.222	0.081
Unknown TAG species (52:11)	0.229	0.015
TAG (56:5)	0.250	0.078
HexCer (40:0;3)	0.265	0.022
Unknown TAG species (50:10)	0.277	0.034
Cer (42:1;3)	0.280	0.097
PS (38:0)	0.305	0.081
TAG (56:5)	0.308	0.078
Unknown TAG species (52:10)	0.310	0.078
Unknown TAG species (54:4)	0.322	0.078
TAG (48:3)	0.336	0.081
TAG (52:6)	0.353	0.081
Unknown TAG species (52:10)	0.393	0.078
Unknown TAG species (52:10)	0.396	0.081

Table 2

Cluster	Size	Lipid types
		Cer, LPC,PC,CE, TAG, DAG PS, PS-O,
Cluster 1	92	SM
Cluster 2	10	LPC, LPE
Cluster 3	69	Cer, LPC,PC,CE,PC, PC-O, PE, PS, TAG
Cluster 4	61	Cer, DAG, TAG PE
Cluster 5	55	PE, DAG, Cer, PE-O, TAG
Cluster 6	39	TAG
Cluster 7	31	TAG
Cluster 8	32	TAG
Cluster 9	34	TAG
Cluster 10	30	TAG
Cluster 11	9	TAG
Cluster 12	25	TAG

Figure Legends

Figure 1. Study Design. In this study, patients with SRSE were recruited into a phase I/II clinical trial and treated with a 4:1 (fat:carbohydrate and protein in grams) ratio ketogenic diet (KD). Samples (blood and urine) and clinical measurements were collected at baseline: prior to KD (n=10), Week 1: after 1 week of KD (n=8) , and Week 2: after 2 weeks of KD (n=5). Ketosis was confirmed by urine acetoacetate ≥ 40 mg/dL and/or serum β -hydroxybutyrate ≥ 2 mmol/L. Lipidomics, cytokine and chemokine measurements were performed in longitudinal settings. Then, univariate and multivariate data analyses were performed to determine the potential impact of diet on circulating lipids and inflammatory biomarkers.

Figure 2. Overview of the lipidome in the longitudinal samples. A) ASCA score plots. B) PC1 score plot based on ASCA. These scores represent the lipidomics dataset arranged according to time of sampling in the ASCA score plot. Here each sample is represented by a point and colored according to the time of sample collection. Samples with similar scores are clustered together. (C) The corresponding PC1 loading plot. The loadings explain the pattern seen in the score plot which provides the means to interpret the class specific lipid alterations related to KD.

Figure 3. Correlation of individual TGs with the study week (baseline to week 2). The x-axis is the acyl carbon number and the y-axis is the acyl double-bond count. The dots are coloured according to the spearman coefficient.

Figure 4. The ketogenic diet reduces pro-inflammatory cytokines in patients with refractory status epilepticus. Serum levels of (A) IL-6, (B) CCL3, (C) CCL4, and (D) CXCL13 were measured before patients initiated the ketogenic diet (pre-ketogenic diet) and one to two weeks after diet initiation (on-ketogenic diet). Data are expressed as the index of each cytokine with each patient baseline set to 100 (arbitrary units). Data were analyzed by a one-way paired t-test. There was a significant reduction in IL-6 (*P=0.0047) and CXCL13 (*P=0.025) in patients on the diet as compared to their baseline samples, but not in CCL3 (P=0.0854) or CCL4 (0.1124). Samples found to be statistical outliers are circled in red and are not included in analyses.

Figure 5. Correlation coefficients illustrated by a heat map. The correlation analysis was performed between lipid clusters and other measurements including cytokine measurements, ketones, patient demographics as well as outcome measure as listed in Fig.1. a) Baseline and b) Week 1 samples. The circles in the plot represents the spearman correlation coefficient between the measurements. Here, purple gradient represents the strength positive correlation while the dark orange gradient indicates strength of negative correlation (red X denote the p values <0.05). The size of circle represent the strength of the correlation coefficient. Bigger circle mean higher correlation coefficient.

Figure 6. A. PLS-DA model showing the separation of patients who have a good outcome (mRS ≤ 3 , green) compared to patients with a worse outcome (mRS ≥ 4 , red). B. Plot showing the variable importance versus the regression vector for the lipids which impact the PLS-DA model. Metabolites at the top are increased in patients who do poorly compared to the lipids at the bottom which are decreased in patients who do poorly.

Patient legend

Baseline

Week1